| Literature DB >> 29660464 |
Philippe Berben1, Annette Bauer-Brandl2, Martin Brandl2, Bernard Faller3, Gøril Eide Flaten4, Ann-Christin Jacobsen2, Joachim Brouwers1, Patrick Augustijns5.
Abstract
Cell-free permeation systems are gaining interest in drug discovery and development as tools to obtain a reliable prediction of passive intestinal absorption without the disadvantages associated with cell- or tissue-based permeability profiling. Depending on the composition of the barrier, cell-free permeation systems are classified into two classes including (i) biomimetic barriers which are constructed from (phospho)lipids and (ii) non-biomimetic barriers containing dialysis membranes. This review provides an overview of the currently available cell-free permeation systems including Parallel Artificial Membrane Permeability Assay (PAMPA), Phospholipid Vesicle-based Permeation Assay (PVPA), Permeapad®, and artificial membrane based systems (e.g. the artificial membrane insert system (AMI-system)) in terms of their barrier composition as well as their predictive capacity in relation to well-characterized intestinal permeation systems. Given the potential loss of integrity of cell-based permeation barriers in the presence of food components or pharmaceutical excipients, the superior robustness of cell-free barriers makes them suitable for the combined dissolution/permeation evaluation of formulations. While cell-free permeation systems are mostly applied for exploring intestinal absorption, they can also be used to evaluate non-oral drug delivery by adjusting the composition of the membrane.Entities:
Keywords: Artificial membrane insert system (AMI-system); Oral drug delivery; Parallel artificial membrane permeability assay (PAMPA); Permeability; Permeapad®; Phospholipid vesicle-based permeation assay (PVPA)
Mesh:
Substances:
Year: 2018 PMID: 29660464 DOI: 10.1016/j.ejps.2018.04.016
Source DB: PubMed Journal: Eur J Pharm Sci ISSN: 0928-0987 Impact factor: 4.384